PATTERN OF ANTIHYPERTENSIVE THERAPY AMONG DIABETIC-HYPERTENSIVE PATIENTS IN ZEWDITU MEMORIAL HOSPITAL, ADDIS ABABA

Authors

  • Hailu Abera Mulatu St. Paul's Hospital Millennium Medical College
  • Mihret Woldemichael Department of Pharmacy, Zewditu Memorial Hospital

Abstract

ABSTRACT

Introduction: Diabetes mellitus is becoming a common chronic disease in both developed and developing nations and is associated with a significant cardiovascular disease morbidity and mortality. The presence of hypertension in patients with diabetes mellitus will double the risk of cardiovascular disease including coronary heart disease, congestive heart failure, ischemic and hemorrhagic stroke, renal failure and peripheral arterial disease.

Objective: The aim of this study was to assess the pattern of antihypertensive drug therapy among diabetic-hypertensive patients in Zewditu Memorial Hospital Diabetic Clinic in Addis Ababa.

Methods: This is a hospital based retrospective review of medical records of 382 diabetic-hypertensive patients who visited Zewditu Memorial Hospital Diabetic Clinic in the period between August 2014 and January 2015.

Results: The most frequently prescribed antihypertensive drug classes were ACEI in 321 (84%) followed by CCB in 229(60%) and BB in 145 (38%) patients. Enalapril, nifedipine, atenolol, losartan and hydrochlorthiazide was the only ACEI, CCB, BB, ARB and DI prescribed respectively. Enalapril was used as a monotherapy in 73(19%) and nifedipine in 26(7%) patients. The recommended target SBP <140 mmHg and DBP <90mmHg was achieved in only 57(15%) patients while the rest 325(85%) did not attain the target blood pressure. Renal function was assessed in 351(92%) patients, of whom 23(6%) had renal impairment with an estimated GFR < 60 ml/min.

Conclusion: The pattern of antihypertensive drug therapy in our patients was consistent with the current treatment guidelines. However, majority of diabetic-hypertensive patients did not reach target blood pressure.

Author Biography

Hailu Abera Mulatu, St. Paul's Hospital Millennium Medical College

Assistant Professor of MedicineSt. Paul's Hospital Millennium Medical College

References

REFERENCES

Powers AC. Diabetes. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, editors. Harrison’s: principles of internal medicine. New York: McGraw-Hill; 2012. p 2968-3009.

International Diabetes Federation Atlas, 6th ed, 2013. Available from http://www.idf.org/diabetesatlas.

Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective Observational Study. BMJ. 2000 Aug; 321(7258):412-9.

Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Diabetes Care. 2008; 31(2):353–60.

Dickstein K and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. The Lancet. 2002; 360 (9335):752–60.

Raval D, Yadav AR, Bhansali A, and Tiwari P. Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. Int J Hypertension. Volume 2012 (2012), Article ID 520915, 9 pages. Available from http://dx.doi.org/10.1155/2012/520915.

Aram V, Chobanian AV, Bakris GL, et al. Joint National Committee on Prevention, Detection, evaluation, and treatment of high blood pres­sure. National heart, lung, and blood institute; National high blood pressure education pro­gram coordinating committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-52.

James PA, Oparil S., Carter BL, et al. Report from the panel members appointed to eight report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2014;311(5):507-20.

Estacio RO, Jeffers BW, Hiatt WR, Bigger SL staff, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New Engl J Med 1998; 338(10):645–52.

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;351(9118):1755-62.

Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Int Med. 2005; 165(12):1410–1419.

ALLHAT Officers and Coordinators for the ALLHAT collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-2997.

Brodalko B, Ruminska M, Chylinska P. An evaluation of the incidence and treatment of hypertension in diabetic patients based on a survey and a review of hospital documentation. Diabetologia Clinical Documents 2007;7:24-7.

Berlowitz DR, Ash AS, Hickey EC, Friediman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998:339:1957-63.

Gerstein HC, Yusuf S, Mann JF, Hoogwerf B, Zinman B, Held C, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-9.

Lewis E, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the Angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345 (12):851-60.

Downloads

Published

2016-03-24

Issue

Section

Original Article